



Name	Chun-Jen Liu
Affiliation	Hepatitis Research Center, National Taiwan University Hospital
Country	Taiwan
Major Field	hepatitis B, hepatitis C, HCC, and steatotic liver disease.

Educational Background

Chun-Jen LIU is a Professor at the Department of Internal Medicine, National Taiwan University College of Medicine. He achieved his MD and PhD at the National Taiwan University. He is currently Director of the Hepatitis Research Center, Director of Gastroenterology and Hepatology, and Director of Clinical Trial Center, National Taiwan University Hospital. He ever delivered the JGH Foundation Emerging Leader Lecture in APDW 2013. Recently, he received NTUH outstanding Research Award. He is now the President of the Taiwan Association for the Study of the Liver. He is also the associate editor, the Journal of the Formosan Medical Association, and Journal of Microbiology, Immunology and Infection. He has authored 380 papers in international, peer-reviewed journals.

Main Scientific Publications

1. Liu CJ, Chen PJ, Lai MY, Kao JH, Chang CF, Wu HL, Shau WY, Chen DS. A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. *Gastroenterology* 2003;124:80-90.
2. Liu CJ, Chen PJ, Jeng YM, Huang WL, Lai MY, Kao, JH, Chen DS. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. *J Hepatol* 2005;43:235-242.
3. Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. *J Hepatol* 2006;44:39-46.
4. Liu CJ, Lai MY, Chao YC, Liao LY, Yang SS, Hsiao TJ, Hsieh TY, Lin CL, Hu JT, Chen CL, Chen PJ, Kao JH, Chen DS. Interferon alfa-2b with and without Ribavirin for Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Randomized Study. *Hepatology* 2006;43:742-749.
5. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SC, Chen PJ. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and dose-finding. *J Hepatol* 2009;50:958-968.
6. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis C and B viruses. *Gastroenterology* 2009;136:496-504.
7. Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osinusi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Efficacy of ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected with HBV. *Gastroenterology* 2018;154:989-997.